<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008514</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08177</org_study_id>
    <nct_id>NCT01008514</nct_id>
  </id_info>
  <brief_title>Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer</brief_title>
  <official_title>A Single Institution, Prospective, Non-randomized Study of Partial Breast Irradiation Using the MammoSite Radiation Therapy System (Breast Brachytherapy Applicator)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near&#xD;
      a tumor to kill tumor cells. It may also cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well partial-breast radiation therapy works in&#xD;
      treating women with early-stage breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To examine the efficacy of MammoSite® Radiation Therapy System (RTS) in delivering&#xD;
           partial-breast irradiation to women with early-stage breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the toxicities associated with MammoSite® RTS in these patients.&#xD;
&#xD;
        -  To evaluate the cosmetic results in the breast after brachytherapy with the MammoSite®&#xD;
           RTS.&#xD;
&#xD;
        -  To correlate the cosmetic results with the use of chemotherapy, volume of the implant,&#xD;
           and distance from the implant to the skin.&#xD;
&#xD;
        -  To correlate the local recurrence rate with time between surgery and implant.&#xD;
&#xD;
      OUTLINE: Patients undergo placement of the MammoSite® Radiation Therapy System (RTS) device&#xD;
      into the cavity where the tumor was removed either at the time of surgery or percutaneously&#xD;
      under ultrasound guidance after surgery. Within 2-5 days after the device implant, patients&#xD;
      undergo partial-breast irradiation delivered by MammoSite® RTS twice daily for 5 days.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding issues and Principal Investigator leaving the institution&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of local recurrence</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Local recurrence is defined as either invasive or non-invasive local recurrence within the target volume.&#xD;
Ipsilateral elsewhere recurrence is defined as either invasive or non-invasive local recurrence outside of the target volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
    <time_frame>up to 30 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic results</measure>
    <time_frame>up to 30 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated partial breast irradiation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intracavitary balloon brachytherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ductal carcinoma in situ (DCIS) of the breast or invasive&#xD;
             breast adenocarcinoma&#xD;
&#xD;
               -  Stage 0, I, or II (T2, N0; tumor size ≤ 3 cm) disease&#xD;
&#xD;
               -  Pathologic staging of the axilla preferred&#xD;
&#xD;
                    -  Clinical staging of the axilla allowed for patients ≥ 70 years of age with&#xD;
                       hormone receptor-positive tumors&#xD;
&#xD;
          -  Unicentric tumor&#xD;
&#xD;
               -  Microscopic multifocality allowed as long as the total tumor size is ≤ 3 cm&#xD;
&#xD;
          -  Must have undergone lumpectomy as definitive surgery&#xD;
&#xD;
               -  Negative surgical margins, defined as no tumor at the inked margin of resection&#xD;
                  after final surgery&#xD;
&#xD;
                    -  Re-excision to obtain negative margins allowed&#xD;
&#xD;
          -  Must have adequate skin spacing between balloon surface and surface of the skin and&#xD;
             lung (≥ 7 mm)&#xD;
&#xD;
          -  No multicentric carcinoma (invasive or DCIS) in more than one quadrant&#xD;
&#xD;
          -  No clinically or pathologically positive regional lymph nodes&#xD;
&#xD;
          -  No extensive intraductal component, defined as DCIS extending beyond the primary&#xD;
             invasive component into normal breast parenchyma and composing &gt; 25% of the primary&#xD;
             tumor&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No collagen-vascular disease, including any of the following:&#xD;
&#xD;
               -  Dermatomyositis&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Scleroderma-mixed connective tissue disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

